XERS - Xeris Pharmaceuticals GAAP EPS of -$0.12 beats by $0.05 revenue of $33.2M beats by $2.43M
2023-05-09 07:03:17 ET
- Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q1 GAAP EPS of -$0.12 beats by $0.05 .
- Revenue of $33.2M (+51.5% Y/Y) beats by $2.43M .
- FY2023 Outlook : Total revenue of $135M-$165M vs. consensus of $146.9M; cash utilization from operating activities of $57M-$77M; year-end cash, cash equivalents, and short-term investments of $45M-$65M.
For further details see:
Xeris Pharmaceuticals GAAP EPS of -$0.12 beats by $0.05, revenue of $33.2M beats by $2.43M